Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Liquisolid Technique: A Novel Technique with Remarkable Applications in Pharmaceutics

Author(s): Sahibpreet Singh, Jyoti Singh* and Disha Arora

Volume 21, Issue 1, 2024

Published on: 10 October, 2023

Article ID: e101023222025 Pages: 15

DOI: 10.2174/0115701638258285230921025512

Price: $65

Abstract

Recently, it has been observed that newly developed drugs are lipophilic and have low aqueous solubility issues, which results in a lower dissolution rate and bioavailability of the drugs. To overcome these issues, the liquisolid technique, an innovative and advanced approach, comes into play. This technique involves the conversion of the drug into liquid form by dissolving it in non-volatile solvent and then converting the liquid medication into dry, free-flowing, and compressible form by the addition of carrier and coating material. It offers advantages like low cost of production, easy method of preparation, and compactable with thermo labile and hygroscopic drugs. It has been widely applied for BCS II drugs to enhance dissolution profile. Improving bioavailability, providing sustained release, minimizing pH influence on drug dissolution, and improving drug photostability are some of the other promising applications of this technology. This review article presents an overview of the liquisolid technique and its applications in formulation development.

Graphical Abstract

[1]
Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 2007; 31(5): 249-61.
[http://dx.doi.org/10.1016/j.ejps.2007.05.110] [PMID: 17616376]
[2]
Lu M, Xing H, Jiang J, et al. Liquisolid technique and its applications in pharmaceutics. Asian J Pharmaceut Sci 2017; 12(2): 115-23.
[http://dx.doi.org/10.1016/j.ajps.2016.09.007] [PMID: 32104320]
[3]
Kulkarni AS, Aloorkar NH, Mane MS, Gaja JB. Liquisolid systems: A review. Int J Pharm Sci Nanotechnol 2010; 3: 795-802.
[4]
Elkordy AA, Tan XN, Essa EA. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles. Eur J Pharm Biopharm 2013; 83(2): 203-23.
[http://dx.doi.org/10.1016/j.ejpb.2012.08.004] [PMID: 22960707]
[5]
Deepika G, Gudipati M, Nadendla RR. A comprehensive review on liquisolid tablets. Int J Pharm Sci Rev Res 2021; 67(1): 195-201.
[http://dx.doi.org/10.47583/ijpsrr.2021.v67i01.031]
[6]
Balaji A, Shankar MS, Kavitha B. Liquisolid technology- A latest review. Int J App Pharm 2014; 6(1): 11-9.
[7]
Phoke SV, Hatkar AD, Jaybhaye SS. Improvement of solubility and dissolution by liquisolid compact. J Pharma Care Health Sys 2012; 9(1): 1-6.
[8]
Spiras S, Wang T, Grover R. Effect of powder substrate on dissolution properties of methylclothiazide liqui-solid compacts. Drug Dev Ind Pharm 1999; 25: 63-168.
[9]
Tayel SA, Soliman II, Louis D. Improvement of dissolution properties of Carbamazepine through application of the liquisolid tablet technique. Eur J Pharm Biopharm 2008; 69(1): 342-7.
[http://dx.doi.org/10.1016/j.ejpb.2007.09.003] [PMID: 17949959]
[10]
Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN. Evaluation of in vitro dissolution profile comparison methods of sustained release tramadol hydrochloride liquisolid compact formulations with marketed sustained release tablets. Drug Discov Ther 2010; 4(1): 26-32.
[PMID: 22491149]
[11]
Gavali SM, Pacharane SS, Sankpal SV, Jadhav KR, Kadam VJ. Liquisolid compact: A new technique for enhancement of drug dissolution. Int J Res Pharm Chem 2011; 1: 705-13.
[12]
Nagabandi VK, Ramarao T, Jayaveera KN. Liquisolid compacts: A novel approach to enhance bioavailability of poorly soluble drugs. Int J Pharm Biol Sci 2011; 1: 89-102.
[13]
Grover R, Spireas S, Lau-Cam C. Development of a simple spectrophotometric method for propylene glycol detection in tablets. J Pharm Biomed Anal 1998; 16(6): 931-8.
[http://dx.doi.org/10.1016/S0731-7085(97)00098-8] [PMID: 9547696]
[14]
Sirisha VNL, Sruthi B, Namrata M, et al. A review on liquid solid compacts. Int J Pharm Phytopharmacol Res 2012; 2(2): 116-21.
[15]
Sai PDL, Sivaiah KV, Bonthagarala B, Rao PV. Review on liquisolid compact technology. World J Pharm Res 2014; 4: 293-306.
[16]
Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices. Int J Pharm 2008; 362(1-2): 102-8.
[http://dx.doi.org/10.1016/j.ijpharm.2008.06.022] [PMID: 18647643]
[17]
Rowe RC, Sheskey PJ, Quinn M. Handbook of Pharmaceutical Excipients. (6th ed.). Stuttgart, Germany: Deutscher Apotheker Verlag 2006; p. 918.
[18]
Vajir S, Sahu V, Bakde GN. Effect of dissolution rate by liquisolid compact approach: An overview. Int J Pharm Chem Sci 2012; 1(3): 368-87.
[19]
Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN, Bhise SB. Dissolution rate enhancement of fenofibrate using liquisolid tablet technique. Lat Am J Pharm 2009; 28: 219-25.
[20]
Syed IA, Pavani E. The liquisolid technique: Based drug delivery system. Int J Pharm Sci Drug Res 2012; 4: 88-96.
[21]
Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from liquisolid systems: Speed it up, slow it down. Expert Opin Drug Deliv 2011; 8(2): 191-205.
[http://dx.doi.org/10.1517/17425247.2011.548801] [PMID: 21222556]
[22]
Sharma S. The role of excipients in liquisolid technology. CGC Int J Contemp Technol 2022; 4(2): 296-7.
[23]
Heikkilä T, Salonen J, Tuura J, et al. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 2007; 14(6): 337-47.
[http://dx.doi.org/10.1080/10717540601098823] [PMID: 17701523]
[24]
Phoke SV, Hatkar AD, Borade AS, Rawat SS, Vyas GV. Review on improvement of solubility and dissolution by liquisolid compact. Int Res J Mod Eng Technol Sci 2022; 4(12): 1083-91.
[25]
Vraníková B, Gajdziok J. Liquisolid systems and aspects influencing their research and development. Acta Pharm 2013; 63(4): 447-65.
[http://dx.doi.org/10.2478/acph-2013-0034] [PMID: 24451071]
[26]
Hentzschel CM, Alnaief M, Smirnova I, Sakmann A, Leopold CS. Enhancement of griseofulvin release from liquisolid compacts. Eur J Pharm Biopharm 2012; 80(1): 130-5.
[http://dx.doi.org/10.1016/j.ejpb.2011.08.001] [PMID: 21846502]
[27]
Yadav VB, Yadav AV. Improvement of solubility and dissolution of indomethacin by liquisolid and compaction granulation technique. J Pharm Sci Res 2009; 1: 44-51.
[28]
Fahmy R, Kassem M. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2008; 69(3): 993-1003.
[http://dx.doi.org/10.1016/j.ejpb.2008.02.017] [PMID: 18396390]
[29]
Bindu MB, Kusum B, Banji D. Novel strategies for poorly water soluble drugs. Int J Pharm Sci Rev Res 2010; 4(3): 1-5.
[30]
Patel U, Modi D, Shah D, Shah C, Patel H. Review on liquisolid compacts: A novel approach to enhance solubility of poorly soluble drugs. J Pharm Sci Bioscientific Res 2016; 6(5): 706-12.
[31]
Rokade M, Khandagale P, Phadtare D. Liquisolid compact techniques: A review. Int J Curr Pharm Res 2018; 10(4): 1.
[http://dx.doi.org/10.22159/ijcpr.2018v10i4.28465]
[32]
Panda S, Varaprasad R, Priyanka K, Swain RP. Liquisolid technique: A novel approach for dosage form design. Int J Appl Pharmaceut 2017; 9(3): 8.
[http://dx.doi.org/10.22159/ijap.2017v9i3.18698]
[33]
Sharma A, Jain CP. Techniques to enhance solubility of poorly soluble drugs: A review. J Glob Pharma Technol 2010; 2: 18-28.
[34]
Agiba AM. Liquisolid technology: A State-of-the-art review on the current state, challenges, new and emerging technologies for next generation. Curr Drug Deliv 2020; 17(9): 736-54.
[http://dx.doi.org/10.2174/1567201817999200729121914] [PMID: 32729418]
[35]
Pawar JD, Jagtap RS, Doijad RC, et al. Liquisolid compacts: A promising approach for solubility enhancement. J Drug Deliv Ther 2017; 7(4)
[http://dx.doi.org/10.22270/jddt.v7i4.1466]
[36]
Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm 2007; 341(1-2): 26-34.
[http://dx.doi.org/10.1016/j.ijpharm.2007.03.034] [PMID: 17498898]
[37]
Kumar RS, Sai JD. Liquisolid compacts: A review. J Drug Deliv Ther 2019; 9(4-A): 880-3.
[http://dx.doi.org/10.22270/jddt.v9i4-A.3706]
[38]
Bhavya E, Dhere MD. Liquisolid compacts technique of poor water soluble drugs: An overview. Res J Pharma Technol 2021; 5569–5572: 5569-72.
[http://dx.doi.org/10.52711/0974-360X.2021.00970]
[39]
Patel BB, Shah C. Recent research on liquisolid technology for solubility enhancement-a review. Int J Adv Pharm 2016; 5: 1-7.
[40]
Chaumeil JC. Micronisation, a method of improving the bioavailability of poorly soluble drugs, methods and findings in experimental and clinical pharmacology. Methods Find Exp Clin Pharmacol 2000; 10: 17-28.
[41]
Vippagunta SR, Wang Z, Hornung S, Krill SL. Factors affecting the formation of eutectic solid dispersions and their dissolution behavior. J Pharm Sci 2007; 96(2): 294-304.
[http://dx.doi.org/10.1002/jps.20754] [PMID: 17051588]
[42]
Rawat A, Verma S, Kaul M, Saini S. Solid dispersion: A strategy for solubility enhancement. Int J Pharm Tech 2011; 3(2): 1062-99.
[43]
Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21(2): 201-30.
[http://dx.doi.org/10.1023/B:PHAM.0000016235.32639.23] [PMID: 15032302]
[44]
Seedher N, Kanojia M, Mumper RJ. Micellar solubilization of some poorly soluble antidiabetic drugs: A technical note. AAPS PharmSciTech 2008; 9(2): 431-6.
[http://dx.doi.org/10.1208/s12249-008-9057-5] [PMID: 18431666]
[45]
Hanafy N, El-Kemary M, Leporatti S. Micelles structure development as a strategy to improve smart cancer therapy. Cancers 2018; 10(7): 238.
[http://dx.doi.org/10.3390/cancers10070238] [PMID: 30037052]
[46]
Vemula V R, Lagishetty V, Lingala S. Cheminform abstract: Solubility enhancement techniques. ChemInform 2011; 42(41)
[http://dx.doi.org/10.1002/chin.201141266]
[47]
Poulson BG, Alsulami QA, Sharfalddin A, et al. Cyclodextrins: Structural, chemical, and physical properties, and applications. Polysaccharides 2021; 3(1): 1-31.
[http://dx.doi.org/10.3390/polysaccharides3010001]
[48]
Kadam SV, Shinkar DM, Saudagar RB. Review on solubility enhancement techniques. IJPBS 2013; 3(3): 462-75.
[49]
Jagtap S, Magdum C, Jadge D, Jagtap R. Solubility enhancement technique: A review. J Pharmaceut Sci Res 2018; 10(9): 2205-11.
[50]
Mohammadi-Samani S, Ghasemiyeh P. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Appli-cations, advantages and disadvantages. Res Pharm Sci 2018; 13(4): 288-303.
[http://dx.doi.org/10.4103/1735-5362.235156] [PMID: 30065762]
[51]
Lee MK. Liposomes for enhanced bioavailability of water-insoluble drugs: In vivo evidence and recent approaches. Pharmaceutics 2020; 12(3): 264.
[http://dx.doi.org/10.3390/pharmaceutics12030264] [PMID: 32183185]
[52]
Barani M, Sangiovanni E, Angarano M, et al. Phytosomes as innovative delivery systems for phytochemicals: A comprehensive review of literature. Int J Nanomedicine 2021; 16: 6983-7022.
[http://dx.doi.org/10.2147/IJN.S318416] [PMID: 34703224]
[53]
Khan I, Khan ML, Khan U. Liquisolid technology: An emerging and advance technique for enhancing solubilization. PharmaTutor 2014; 2(6): 31-41.
[54]
Hasanandini J, Parthibans S, Vilkeuwari A. Dissolution enhancement technique of poorly soluble drug by liquisolid compact. Int J Res Pharm Nanol Sci 2014; 3: 298-304.
[55]
Manpreet K, Rajni B, Sandeep A. Liquisolid technology: A review. Int J Adv Pharm Sci 2013; 4: 1-5.
[56]
Hentzschel CM, Sakmann A, Leopold CS. Suitability of various excipients as carrier and coating materials for liquisolid compacts. Drug Dev Ind Pharm 2011; 37(10): 1200-7.
[http://dx.doi.org/10.3109/03639045.2011.564184] [PMID: 21449826]
[57]
Anjan KM, Sastry GM, Ranjit PS, Murthy PN, Narahari NP. Liquisolid technique: A novel approach in pharmaceutical formulation de-velopment. J Chem Pharm Res 2014; 6: 529-43.
[58]
Chella N, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B 2012; 2(5): 502-8.
[http://dx.doi.org/10.1016/j.apsb.2012.07.005]
[59]
Elkhodairy AK, Samy MW. Optimization and evaluation of micromeritic and release properties of high dose flutamide liquisolid sys-tems. Lett Drug Des Discov 2012; 9(3): 336-44.
[http://dx.doi.org/10.2174/157018012799129873]
[60]
Bonthagarala B, Lakshmi Sai PD, K VS, G AK, Rao BN, Dasari V. Enhancement of dissolution rate of Clofibrate BCS Class –II drug by using liquisolid compact technology. Int J Biol Adv Res 2015; 6(3): 288.
[http://dx.doi.org/10.7439/ijbar.v6i3.1891]
[61]
Mohan D, Chivate AN. Formulation and evaluation of liquisolid compact on NSAID naproxen. Res J Pharm Technol 2014; 7: 284-9.
[62]
Sahoo PK, Dash S, Sahoo AC, Mishra B. Dissolution enhancement of prednisolone using liquisolid compacts. Int J Pharm Sci Res 2021; 13(12): 666-72.
[63]
Aher SS, Rane TP, Saudagar RB. Formulation and evaluation of lercanidipine hydrochloride by liquisolid technique. IJPRR 2016; 7: 35-52.
[64]
Dias RJ, Mali KK, Ghorpade VS, Havaldar VD, Mohite VR. Formulation and evaluation of carbamazepine liquisolid compacts using novel carriers. Indian J Pharmaceut Edu Res 2017; 51(2s): s69-78.
[http://dx.doi.org/10.5530/ijper.51.2s.52]
[65]
Kalbhor M, Bhosale A, Patil R, Kakade S. Formulation and evaluation of telmisartan liquisolid compact tablets. Human J 2017; 9(4): 152-82.
[66]
Shete A, Salunkhe A, Yadav A, Sakhare S, Doijad R. Neusilin based liquisolid compacts of albendazole: Design, development, characterization and in vitro anthelmintic activity. J Res Pharma 2019; 23(3): 441-56.
[http://dx.doi.org/10.12991/jrp.2019.151]
[67]
Prajapati ST, Bulchandani HH, Patel DM, Dumaniya SK, Patel CN. Formulation and evaluation of liquisolid compacts for olmesartan medoxomil. J Drug Deliv 2013; 2013: 1-9.
[http://dx.doi.org/10.1155/2013/870579] [PMID: 24232077]
[68]
Deveswaran R, Madhavan V, Vittal GV, Basavaraj BV, Bharath S. Formulation and characterization of ketoprofen liquisolid compacts by Box-Behnken design. Int J Pharm Investig 2012; 2(3): 150-6.
[http://dx.doi.org/10.4103/2230-973X.104398] [PMID: 23373006]
[69]
Patel G, Pandya D, Gandhi P, Parikh R. Formulation of modified liquisolid compact for dissolution enhancement of raloxifene hydrochloride. Pharm Technol 2021; 45(7): 48-52.
[70]
Cirri M, Mura P, Valleri M, Brunetti L. Development and characterization of liquisolid tablets based on mesoporous clays or silicas for improving glyburide dissolution. Pharmaceutics 2020; 12(6): 503.
[http://dx.doi.org/10.3390/pharmaceutics12060503] [PMID: 32492869]
[71]
Akinlade B, Elkordy AA, Essa EA, Elhagar S. Liquisolid systems to improve the dissolution of furosemide. Sci Pharm 2010; 78(2): 325-44.
[http://dx.doi.org/10.3797/scipharm.0912-23] [PMID: 21179350]
[72]
Kapure VJ, Pande VV, Deshmukh PK. Dissolution enhancement of rosuvastatin calcium by liquisolid compact technique. J Pharm 2013; 2013: 1-9.
[http://dx.doi.org/10.1155/2013/315902] [PMID: 26555972]
[73]
Venkateswarlu K, Preethi JK, Chandrasekhar KB. Enhancement of loperamide dissolution rate by liquisolid compact technique. Adv Pharm Bull 2016; 6(3): 385-90.
[http://dx.doi.org/10.15171/apb.2016.050] [PMID: 27766222]
[74]
Saeedi M, Akbari J, Morteza-Semnani K, Enayati-Fard R, Sar-Reshteh-Dar S, Soleymani A. Enhancement of dissolution rate of indo-methacin: Using liquisolid compacts. Iran J Pharm Res 2011; 10(1): 25-34.
[PMID: 24363677]
[75]
Vemula S, Aila S, Bontha V. Formulation and evaluation of ezetimibe liquisolid tablets: An approach to enhance the dissolution rate. Br J Pharm Res 2015; 7(6): 440-50.
[http://dx.doi.org/10.9734/BJPR/2015/19125]
[76]
Bhairav BA, Jadhav MS, Saudagar RB. Formulation and evaluation of liquisolid tablet of felodipine. World J Pharm Pharm Sci 2016; 5(7): 1670-85.
[77]
Rajab NA. Preparation and in vitro evaluation of lacidipine oral liquid solid tablet as an approach of solubility and dissolution rate enhancement. Int J Appl Pharmaceut 2018; 10(1): 145.
[http://dx.doi.org/10.22159/ijap.2018v10i1.22313]
[78]
Kondawar M, Varne B. Enhancement of dissolution properties of candesartan using liquisolid technique. Int J Adv Pharm Res 2013; 4: 2503-13.
[79]
Saraswathi B, Rajendar M. Liquisolid technology for enhancing the dissolution profile of irbesartan by using different non volatile sol-vents and carrier materials. J Pharm Pharm Sci 2014; 3(10): 839-54.
[80]
Pardhi DM, Shivhare UD, Mathur VB, Bhusari KP. Liquisolid technique for enhancement of dissolution properties of carvedilol. Pharm Lett 2010; 2: 412-27.
[81]
Khadka P, Ro J, Kim H, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J Pharmaceut Sci 2014; 9(6): 304-16.
[http://dx.doi.org/10.1016/j.ajps.2014.05.005]
[82]
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3): 413-20.
[http://dx.doi.org/10.1023/A:1016212804288] [PMID: 7617530]
[83]
Kanikkannan N. Technologies to improve the solubility, dissolution and bioavailability of poorly soluble drugs. J Anal Pharm Res 2018; 7(1)
[http://dx.doi.org/10.15406/japlr.2018.07.00198]
[84]
Khaled KA, Asiri YA, El-Sayed YM. In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs. Int J Pharm 2001; 222(1): 1-6.
[http://dx.doi.org/10.1016/S0378-5173(01)00633-0] [PMID: 11404027]
[85]
Badawy MA, Kamel AO, Sammour OA. Use of biorelevant media for assessment of a poorly soluble weakly basic drug in the form of liquisolid compacts: In vitro and in vivo study. Drug Deliv 2016; 23(3): 808-17.
[http://dx.doi.org/10.3109/10717544.2014.917442] [PMID: 24892630]
[86]
Dias R, Ranjan S, Mali K, Ghorpade V, Havaldar V. Liquisolid compacts of meloxicam: In-vitro and in-vivo evaluation. Egyptian Pharmaceut J 2017; 16(2): 112.
[http://dx.doi.org/10.4103/epj.epj_9_17]
[87]
Sura R S, Subrahmanyam C, Rachamalla S S. Design and evaluation of liquisolid compacts of nebivolol hydrochloride. Int J Appl Pharm 2022; 14(2): 293-307.
[http://dx.doi.org/10.22159/ijap.2022v14i2.43657]
[88]
El-Houssieny BM, Wahman L, Arafa NMS. Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. Biosci Trends 2010; 4(1): 17-24.
[PMID: 20305340]
[89]
Chopra DK, Madhab DK, Sahu PK. Improvement of oral bioavailability of azilsartan medoxomil by lipid based liquisolid compacts: In vitro and in vivo evaluation. Int Res J Pharma 2019; 9(12): 134-9.
[http://dx.doi.org/10.7897/2230-8407.0912306]
[90]
Yehia SA, El-Ridi MS, Tadros MI, El-Sherif NG. Enhancement of the oral bioavailability of fexofenadine hydrochloride via cremophor® el-based liquisolid tablets. Adv Pharm Bull 2015; 5(4): 569-81.
[http://dx.doi.org/10.15171/apb.2015.077] [PMID: 26819931]
[91]
Sharma V, Pathak K. Liquisolid system of paclitaxel using modified polysaccharides: In vitro cytotoxicity, apoptosis study, cell cycle analysis, in vitro mitochondrial membrane potential assessment, and pharmacokinetics. Int J Biol Macromol 2019; 137: 20-31.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.06.188] [PMID: 31252010]
[92]
Suram D, Narala A, Veerabrahma K. Development, characterization, comparative pharmacokinetic and pharmacodynamic studies of iloperidone solid SMEDDS and liquisolid compact. Drug Dev Ind Pharm 2020; 46(4): 587-96.
[http://dx.doi.org/10.1080/03639045.2020.1742142] [PMID: 32162981]
[93]
Khames A. Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. Drug Deliv 2017; 24(1): 328-38.
[http://dx.doi.org/10.1080/10717544.2016.1250140] [PMID: 28165818]
[94]
Thakur N, Khokra SL, Sharma D, Thakur NS, Purohit R, Arya V. A review on pharmaceutical application of liquisolid technique. Am J Pharmtech Res 2011; 1: 1-18.
[95]
Patra CN, Priya R, Swain S, Kumar Jena G, Panigrahi KC, Ghose D. Pharmaceutical significance of Eudragit: A review. Future J Pharmaceut Sci 2017; 3(1): 33-45.
[http://dx.doi.org/10.1016/j.fjps.2017.02.001]
[96]
Aliyah A, Utomo E, Permana A D. Development of liquisolid formulation for improved sustained release of propranolol hydrochloride. Int J Appl Pharm 2021; 13(2): 210-6.
[http://dx.doi.org/10.22159/ijap.2021v13i2.40354]
[97]
Pavani E, Noman S, Syed IA. Liquisolid technique based sustained release tablet of trimetazidine dihydrochloride. Drug Invention Today 2013; 5(4): 302-10.
[http://dx.doi.org/10.1016/j.dit.2013.08.006]
[98]
Elkordy AA, Essa EA, Dhuppad S, Jammigumpula P. Liquisolid technique to enhance and to sustain griseofulvin dissolution: Effect of choice of non-volatile liquid vehicles. Int J Pharm 2012; 434(1-2): 122-32.
[http://dx.doi.org/10.1016/j.ijpharm.2012.05.072] [PMID: 22677418]
[99]
Nnamani P, Ugwu A, Ibezim E, et al. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternateday regimen for malaria treatment to improve patient compliance. Int J Nanomedicine 2016; 11: 6365-78.
[http://dx.doi.org/10.2147/IJN.S92755] [PMID: 27932882]
[100]
El-Hammadi M, Awad N. Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release. AAPS PharmSciTech 2012; 13(1): 53-8.
[http://dx.doi.org/10.1208/s12249-011-9719-6] [PMID: 22101967]
[101]
Chella N, Narra N, Rama Rao T. Preparation and characterization of liquisolid compacts for improved dissolution of telmisartan. J Drug Deliv 2014; 2014: 1-10.
[http://dx.doi.org/10.1155/2014/692793] [PMID: 25371826]
[102]
Tønnesen HH. Formulation and stability testing of photolabile drugs. Int J Pharm 2001; 225(1-2): 1-14.
[http://dx.doi.org/10.1016/S0378-5173(01)00746-3] [PMID: 11489550]
[103]
Khames A. Liquisolid technique: A promising alternative to conventional coating for improvement of drug photostability in solid dosage forms. Expert Opin Drug Deliv 2013; 10(10): 1335-43.
[http://dx.doi.org/10.1517/17425247.2013.798297] [PMID: 23706099]
[104]
Spireas S, Bolton S M. Liquisolid systems and methods of preparing same. US6096337A, 2000.
[105]
Wagner K G, Lamprecht A, Kroma A K, Grisic D, Denninger A, Becker T. Liquisolid pharmaceutical formulation and process for manufacturing. WO2021219817A1, 2021.
[106]
Monsuur F H. Porous silica gel as a carrier for liquid technologies. US20150366805A1, 2015.
[107]
Wolf C, Krekeler A, Sedlmayr M. Selexipag formulation in liquisolid systems. WO2018109158A1, 2018.
[108]
El–Say K M, Alotaibi F O, Alhakamy N A, Omar AM. Liquisolid tablet containing combined dose of tadalafil and dapoxetine. US10744137B1, 2020.
[109]
Wagner K G, Kroma A K, Horaf A, et al. Solid and liquisolid formulations of Corallopyronin A. WO2021219808A1, 2021.
[110]
Singh S K, Kumar R, Gulati M, et al. Novel liquisolid composition of fisetin. AU2021106234A4, 2021.
[111]
Humberto G F, Bianca R P, Diva S, et al. Liquisolid multiparticulate systems for oral administration, process of obtaining the same and their uses. BR102016015553A2, 2018.
[112]
Spireas S. Methods of treatment with metaxalone comprising nonvolatile liquids. US20130245083A, 2013.
[113]
Chaurasiya A, Jagwani A, Jain V, et al. Fast-release solid oral celecoxib composition for the treatment of acute pain. DE202022104280U1, 2022.
[114]
Jadhav NR, Irny PV, Patil US. Solid state behavior of progesterone and its release from Neusilin US2 based liquisolid compacts. J Drug Deliv Sci Technol 2017; 38: 97-106.
[http://dx.doi.org/10.1016/j.jddst.2017.01.009]
[115]
Said Suliman A, Anderson RJ, Elkordy AA. Preparation of novel optimum liquisolid compacts via incorporating water granulation pro-cess to enhance the powder characterizations and dissolution behavior of a poorly soluble drug: Norfloxacin. Powder Technol 2019; 354: 259-70.
[http://dx.doi.org/10.1016/j.powtec.2019.05.071]
[116]
Pezzini BR, Beringhs AO, Ferraz HG, Silva MAS, Stulzer HK, Sonaglio D. Liquisolid technology applied to pellets: Evaluation of the feasibility and dissolution performance using felodipine as a model drug. Chem Eng Res Des 2016; 110: 62-9.
[http://dx.doi.org/10.1016/j.cherd.2016.01.037]
[117]
Vasiljević I, Turković E, Nenadović S, et al. Investigation into liquisolid system processability based on the SeDeM Expert System approach. Int J Pharm 2021; 605(120847): 120847.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120847] [PMID: 34216763]
[118]
Patel J, Dhingani A, Garala K, Raval M, Sheth N. Quality by design approach for oral bioavailability enhancement of Irbesartan by self-nanoemulsifying tablets. Drug Deliv 2014; 21(6): 412-35.
[http://dx.doi.org/10.3109/10717544.2013.853709] [PMID: 24215334]
[119]
El-Sayyad NMEM, Badawi A, Abdullah ME, Abdelmalak NS. Dissolution enhancement of leflunomide incorporating self emulsifying drug delivery systems and liquisolid concepts. Bull Fac Pharm Cairo Univ 2017; 55(1): 53-62.
[http://dx.doi.org/10.1016/j.bfopcu.2017.02.001]
[120]
Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: A clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol 2015; 71(5): 549-67.
[http://dx.doi.org/10.1007/s00228-015-1832-0] [PMID: 25870032]
[121]
Hamed R, Awadallah A, Sunoqrot S, et al. pH-dependent solubility and dissolution behavior of carvedilol-case example of a weakly basic BCS class II drug. AAPS PharmSciTech 2016; 17(2): 418-26.
[http://dx.doi.org/10.1208/s12249-015-0365-2] [PMID: 26202065]
[122]
Ahmad I, Ahmed S, Anwar Z, Sheraz MA, Sikorski M. Photostability and photostabilization of drugs and drug products. Int J Photoenergy 2016; 2016: 1-19.
[http://dx.doi.org/10.1155/2016/8135608]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy